Floris C. Loeff

773 total citations
23 papers, 331 citations indexed

About

Floris C. Loeff is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Genetics. According to data from OpenAlex, Floris C. Loeff has authored 23 papers receiving a total of 331 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 8 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Genetics. Recurrent topics in Floris C. Loeff's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Biosimilars and Bioanalytical Methods (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Floris C. Loeff is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Biosimilars and Bioanalytical Methods (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Floris C. Loeff collaborates with scholars based in Netherlands, United States and Canada. Floris C. Loeff's co-authors include Theo Rispens, Gertjan Wolbink, Femke Hooijberg, J.H. Frederik Falkenburg, Inge Jedema, Henriëtte M. Goselink, Robert L. Saylors, Anisha Kothari, Joshua M. Eichhorn and Timothy C. Chambers and has published in prestigious journals such as The Journal of Immunology, Cancer Research and Annals of Neurology.

In The Last Decade

Floris C. Loeff

22 papers receiving 327 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Floris C. Loeff Netherlands 9 125 76 64 52 52 23 331
Peter Brændstrup Denmark 10 101 0.8× 87 1.1× 28 0.4× 87 1.7× 16 0.3× 22 378
Maud Maho‐Vaillant France 7 256 2.0× 35 0.5× 65 1.0× 33 0.6× 12 0.2× 15 403
G Di Muzio Italy 7 271 2.2× 86 1.1× 170 2.7× 46 0.9× 47 0.9× 11 425
Raphaela Goldbach‐Mansky United States 5 176 1.4× 118 1.6× 112 1.8× 199 3.8× 37 0.7× 14 372
Kristy Wolniak United States 11 236 1.9× 40 0.5× 19 0.3× 69 1.3× 24 0.5× 30 427
Étienne Crickx France 12 150 1.2× 163 2.1× 46 0.7× 30 0.6× 9 0.2× 25 421
Yvonne Sundström Sweden 10 260 2.1× 30 0.4× 161 2.5× 35 0.7× 27 0.5× 13 397
Marguerite Vignon France 10 102 0.8× 114 1.5× 21 0.3× 90 1.7× 19 0.4× 26 324
G. W. Löhr Germany 10 119 1.0× 90 1.2× 30 0.5× 46 0.9× 30 0.6× 18 386
Michele Vigolo Switzerland 11 91 0.7× 36 0.5× 45 0.7× 138 2.7× 13 0.3× 17 325

Countries citing papers authored by Floris C. Loeff

Since Specialization
Citations

This map shows the geographic impact of Floris C. Loeff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Floris C. Loeff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Floris C. Loeff more than expected).

Fields of papers citing papers by Floris C. Loeff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Floris C. Loeff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Floris C. Loeff. The network helps show where Floris C. Loeff may publish in the future.

Co-authorship network of co-authors of Floris C. Loeff

This figure shows the co-authorship network connecting the top 25 collaborators of Floris C. Loeff. A scholar is included among the top collaborators of Floris C. Loeff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Floris C. Loeff. Floris C. Loeff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bluett, James, Floris C. Loeff, Mehmet İtik, et al.. (2025). Quality Assessment of Therapeutic Drug Monitoring Assays of Therapeutic Antibodies Across Europe: An Update. Basic & Clinical Pharmacology & Toxicology. 137(5). e70129–e70129.
2.
Gómez, Alvaro, Floris C. Loeff, Andreas Jönsen, et al.. (2025). Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting. Lara D. Veeken. 64(6). 3797–3805. 1 indexed citations
3.
Loeff, Floris C., Ioannis Parodis, Andreas Jönsen, et al.. (2024). Belimumab concentration measurements using a homologous anti-idiotype immunoassay. Journal of Immunological Methods. 532. 113717–113717. 1 indexed citations
4.
Boekel, Laura, Maurice Steenhuis, Femke Hooijberg, et al.. (2024). Patient-perspective and feasibility of home finger-prick testing to complement and facilitate large-scale research in rheumatology. RMD Open. 10(2). e003933–e003933. 2 indexed citations
5.
6.
Bloem, Karien, et al.. (2023). Drug-tolerant detection of anti-drug antibodies in an antigen-binding assay using europium chelate fluorescence. Journal of Immunological Methods. 514. 113436–113436. 4 indexed citations
7.
Bosma, Angela L., Louise A. A. Gerbens, Floris C. Loeff, et al.. (2023). The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort study. Journal of Dermatological Treatment. 34(1). 2193663–2193663. 2 indexed citations
8.
Steenhuis, Maurice, Floris C. Loeff, Daan J. Touw, et al.. (2023). Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 30(3). 325–335. 8 indexed citations
9.
Wong, Dennis R., Paul J. Boekema, Tessa E H Römkens, et al.. (2023). Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study. Pharmaceutics. 15(3). 972–972. 9 indexed citations
10.
Smit, Adrianus A. J., et al.. (2023). Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non–small cell lung cancer after a single 200 mg administration. Frontiers in Oncology. 12. 960116–960116. 5 indexed citations
11.
12.
Spekhorst, Lotte S., Daphne S. Bakker, Julia Drylewicz, et al.. (2022). Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Allergy. 77(11). 3398–3407. 31 indexed citations
13.
Spekhorst, Lotte S., Marlies de Graaf, Floris C. Loeff, et al.. (2022). Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis. JAMA Dermatology. 158(12). 1409–1409. 10 indexed citations
14.
Kempen, Zoé L. E. van, Maurice Steenhuis, Eileen W Stalman, et al.. (2022). Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis. Annals of Neurology. 93(1). 103–108. 7 indexed citations
15.
Hooijberg, Femke, et al.. (2020). Immunogenicity of TNF-Inhibitors. Frontiers in Immunology. 11. 312–312. 114 indexed citations
16.
Großerichter-Wagener, Christina, et al.. (2020). Biased anti-idiotype response in rabbits leads to high-affinity monoclonal antibodies to biologics. mAbs. 12(1). 1814661–1814661. 6 indexed citations
17.
Loeff, Floris C., Dirk Jan A. R. Moes, Peter A. von dem Borne, et al.. (2019). Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft. Transplant Immunology. 57. 101209–101209. 8 indexed citations
18.
Loeff, Floris C., Willem H. Zoutman, Xiaohang Qiao, et al.. (2018). Loss of the GPI‐anchor in B‐lymphoblastic leukemia by epigenetic downregulation of PIGH expression. American Journal of Hematology. 94(1). 93–102. 2 indexed citations
19.
20.
Kothari, Anisha, Floris C. Loeff, Joshua M. Eichhorn, et al.. (2015). BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells. Cancer Research. 75(7). 1366–1375. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter Brændstrup Breakdown of academic impact, for papers by Maud Maho‐Vaillant Breakdown of academic impact, for papers by G Di Muzio Breakdown of academic impact, for papers by Raphaela Goldbach‐Mansky Breakdown of academic impact, for papers by Kristy Wolniak Breakdown of academic impact, for papers by Étienne Crickx Breakdown of academic impact, for papers by Yvonne Sundström Breakdown of academic impact, for papers by Marguerite Vignon Breakdown of academic impact, for papers by G. W. Löhr Breakdown of academic impact, for papers by Michele Vigolo
Rankless by CCL
2026